Page last updated: 2024-08-24

rhodamine 123 and crizotinib

rhodamine 123 has been researched along with crizotinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, C; Fu, LW; Huang, HB; Liang, YJ; To, KK; Wang, F; Wang, XK; Zhang, X; Zhou, W; Zhou, WJ	1

Other Studies

1 other study(ies) available for rhodamine 123 and crizotinib

Article	Year
Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. British journal of pharmacology, 2012, Volume: 166, Issue:5 Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Crizotinib; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rhodamine 123; Tumor Burden; Xenograft Model Antitumor Assays	2012

Article

Year

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

British journal of pharmacology, 2012, Volume: 166, Issue:5

Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Crizotinib; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rhodamine 123; Tumor Burden; Xenograft Model Antitumor Assays

2012